Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer (original) (raw)
Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
Cancer Research, 2013
N. Robert
Marc Buyse hasn't uploaded this paper.
Let Marc know you want this paper to be uploaded.
Ask for this paper to be uploaded.